Results of treatment with Telmisartan-Amlodipine in hypertensive patients

Thomas W. Littlejohn, Claudio R. Majul, Rafael Olvera, Mary Seeber, Maureen Kobe, Robert Guthrie, Wille Oigman, H. Baglivo, M. Bendersky, E. Kuschnir, P. Rodriguez, A. Villamil, J. Felicio, P. Jardim, O. Kohlman, D. Mion, M. Alpizar, R. Alvarado, J. Illescas, A. MeaneyJ. Parra, R. Peralta, I. Rodriguez, H. Sanchez, S. Trevethan, D. Bernhardi, A. Briel, S. Chetty, E. Janari, J. Jurgens, C. Kahanowitz, D. Lakha, H. Makan, I. Mitha, P. Nel, P. Patel, Z. Vawda, N. Wellington, J. Agaiby, J. Anderson, G. Balaji, H. Bays, N. Bertini, W. Bestermann, K. Blaze, A. Borge, J. Boscia, T. Brobyn, J. Brodnan, V. Brown, T. Cavalieri, C. Chappel, A. Chen, D. Cheung, S. Christensen, S. Chrysant, C. Cooper, T. Copeland, C. De Busk, D. DeSantis, B. Douglas, J. Ervin, P. Fiacco, T. Fiel, J. George, L. Gilderman, R. Gilman, III Glover, A. Goetsch, R. Graf, A. Graff, M. Graves, J. Gutmann, C. Hall, W. Harper, D. Henry, H. Hidalgo, J. Holland, D. Honeycutt, C. Johnson, A. Khan, B. Khan, P. Klaassen, M. Kozinn, S. Kreis, K. Layne, J. Lee, A. Lewin, C. S. Liang, L. Ligon, T. Linder, R. Lipetz, M. Lucas, R. Marple, J. Meli, C. Mello, R. Middleton, S. Mion-Bet, K. Mootoo, A. Murray, J. Naidu, P. Narayan, J. Navarro, J. Neutel, A. Niederman, R. Noble, A. Patron, F. Phillips, W. Pleskow, H. Punzi, G. Raad, T. Raoof, Philip Raskin, A. Razzetti, L. Reed, H. Resnick, J. Schmidt, R. Schreiman, D. Schumacher, M. Seidner, K. Self, G. Serfer, W. Shapiro, J. Silverfield, S. Slabic, R. Sockolov, J. Sparks, R. Struble, C. Thompson, P. Toth, T. Treimer, P. Vrooman, D. Webster, G. Willis, S. Willsie, D. Wright, S. Yates, Karen Shannon, Steven Koval, Ashish Singh

Research output: Contribution to journalArticle

73 Scopus citations

Abstract

This randomized 4 × 4 factorial study determined the efficacy and safety of telmisartan (T) plus amlodipine (A) in hypertensive patients. Adults (N = 1461) with stage 1 or 2 hypertension (baseline blood pressure [BP]: 153.2[12.1]/101.7[4.3] mm Hg) were randomized to 1 of 16 treatment groups with T 0, 20, 40, 80 mg and A 0, 2.5, 5, 10 mg for 8weeks. In-clinic BP reductions were greater with combination therapy than respective monotherapies. The greatest least-square mean systolic/ diastolic BP reductions were observed with T80 mg plus A10 mg (-26.4/ -20.1 mm Hg; P < .05 compared with both monotherapies). BP control was also greatest in the T80-mg plus A10-mg group (76.5% [overall control] and 85.3% [diastolic BP control]), and BP response rates >90% with this combination. Peripheral edema was most common in the A10-mg group (17.8%); however, this rate was notably lower when A was used in combination with T: 11.4% (T20/A10), 6.2% (T40/A10), and 11.3% (T80/ A10).

Original languageEnglish (US)
Pages (from-to)207-213
Number of pages7
JournalJournal of Clinical Hypertension
Volume11
Issue number4
DOIs
StatePublished - May 6 2009

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Results of treatment with Telmisartan-Amlodipine in hypertensive patients'. Together they form a unique fingerprint.

  • Cite this

    Littlejohn, T. W., Majul, C. R., Olvera, R., Seeber, M., Kobe, M., Guthrie, R., Oigman, W., Baglivo, H., Bendersky, M., Kuschnir, E., Rodriguez, P., Villamil, A., Felicio, J., Jardim, P., Kohlman, O., Mion, D., Alpizar, M., Alvarado, R., Illescas, J., ... Singh, A. (2009). Results of treatment with Telmisartan-Amlodipine in hypertensive patients. Journal of Clinical Hypertension, 11(4), 207-213. https://doi.org/10.1111/j.1751-7176.2009.00098.x